Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.165    -0.01 (-5.71%)
Bid:
0.16
Ask:
0.17
Spread: 0.01 (6.25%)
Market Cap: £2.18m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Final Results

29 Jun 2006 12:20

Azure Holdings PLC29 June 2006 Azure Holdings plc REPORT AND FINANCIAL STATEMENTS For the year ended 31 December 2005 CHAIRMAN'S STATEMENT I am pleased to present my first Chairman's statement for the year ended 31December 2005. In the year to 31 December 2005 the Company announced a loss after taxation of£134,000 (2005: £345,000). My predecessor mentioned in his last Chairman's statement that the Company wascontinuing to seek an acquisition and I am pleased we have a target and that thetransaction is moving forward. Your Company not only has a new Board but also a new Nominated Adviser andBroker and we are all working together to bring the proposed transaction to amutually satisfactory conclusion. All parties are aware of the need to complete the transaction by the end ofSeptember and at the time of writing we remain on target to do so. Barry Gold Chairman 29 June 2006 AZURE HOLDINGS PLC PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2005 2005 2004 Note Total Total £'000 £'000 Administrative expenses (134) (345) OPERATING LOSS (134) (345) LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION (134) (345) Taxation - - LOSS ON ORDINARY ACTIVITIES AFTER TAXATION (134) (345) LOSS PER SHARE 3 (0.28p) (0.86p) FULLY DILUTED LOSS PER SHARE 3 (0.28p) (0.86p) The Company has no recognised gains or losses other than the loss for the year. All activities are classed as continuing. AZURE HOLDINGS PLC BALANCE SHEET AT 31 DECEMBER 2005 2005 2004 £'000 £'000 CURRENT ASSETSDebtors 1 7Cash at bank and in hand 1 14 2 21CREDITORS: amounts falling due within one year (205) (90) NET CURRENT LIABILITIES (203) (69) TOTAL ASSETS LESS CURRENT LIABILITIES (203) (69) CAPITAL AND RESERVES Called up share capital 5,475 5,475Share premium account 10,279 10,279Profit and loss account (15,957) (15,823) EQUITY SHAREHOLDERS' FUNDS (203) (69) AZURE HOLDINGS PLC CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2005 2005 2004 £'000 £'000 CASH OUTFLOW FROM OPERATING ACTIVITIES (63) (225) FINANCING Issue of equity shares - 120Loans 50 - DECREASE IN CASH IN THE YEAR (13) (105) AZURE HOLDINGS PLC NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2005 1. Basis of preparation The financial information in this announcement does not constitute statutory financial statements as defined in Section 240 of the Companies Act 1985. The information relating to the year ended 31 December 2004 is an extract from the statutory accounts for that year, which have been delivered to the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain any statements under section 237(2) or (3) of the Companies Act 1985. The auditors have indicated that they will issue an unqualified report on the statutory financial statements for the year ended 31 December 2005. Copies of the Company's Report and Financial Statements will be despatched to shareholders on 29 June 2006 and will be available at the registered office of the Company: One Great Cumberland Place, London W1H 7AL. 2. Going Concern The financial statements have been prepared on the going concern basis. During the year the company incurred a loss of £134,000 and had net liabilities at 31 December 2005 of £203,000. Since the year end, the company has raised £398,000 via the issue of convertible loan stock. The directors continue to actively seek a suitable target for a reverse acquisition. The directors have therefore prepared the financial statements on the going concern basis. The financial statements do not include any adjustments that might arise if this basis was inappropriate. 3. Loss per share Loss per share are calculated using the loss on ordinary activities and the weighted average number of shares detailed below. In calculating fully diluted loss per share, the weighted average number of shares is adjusted for the effect of dilutive share options issued under Company share option schemes. 2005 2004 £'000 £'000 Basic and diluted loss attributable to ordinary (134) (345) shareholders Number Number Weighted average number of ordinary shares 48,317,569 39,767,965 Dilutive share options - - Adjusted weighted average number of ordinary 48,317,569 39,767,965 shares Loss per share (0.28p) (0.86p) Fully diluted loss per share (0.28p) (0.86p) 4. Reconciliation of Operating Loss to Net Cash 2005 2004 Outflow from Operating Activities £'000 £'000 Operating Loss (134) (345) Decrease in debtors 6 - Increase in creditors 65 31 Creditor settled via issue of shares - 89 Net cash outflow from operating activities (63) (225) 5. Reserves Share premium Profit and loss Total account account £'000 £'000 £'000 At 1 January 2005 10,279 (15,823) (5,544) Loss for the year (134) (134) At 31 December 2005 10,279 (15,957) (5,678) 6. Taxation Factors affecting taxation: The tax charge for the year does not equate to the loss before tax at the standard rate of corporation tax in the United Kingdom (30%). The differences are explained below: 2005 2004 £'000 £'000 Loss on ordinary activities before taxation (134) (345) Loss on ordinary activities multiplied by the (40) (104) standard rate of corporation tax in the United Kingdom of 30% (2004:30%) Effect of non-deductible expenses and addition 40 104 to tax losses As 31 December 2005, the Company had accumulated tax losses of £950,000 (2004:£817,000) arising from management expenses and £1,477,000) of capital losses. A deferred tax asset has not been recognised in respect of these losses as they are not expected to be used in the foreseeable future. 7. Dividends The directors are not proposing the payment of a dividend in respect of the year ended 31 December 2005. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Jan 20257:00 amRNSExtension of Evaluation Agreement
29th Jan 20257:00 amRNSNew Evaluation and Option Agreement
15th Jan 202512:47 pmRNSHolding(s) in Company
15th Jan 202511:29 amRNSHolding(s) in Company
14th Jan 20257:00 amRNSHolding(s) in Company
9th Jan 202511:37 amRNSHolding(s) in Company
9th Jan 202511:14 amRNSHolding(s) in Company
8th Jan 20257:00 amRNSHolding(s) in Company
2nd Jan 202511:45 amRNSHolding(s) in Company
31st Dec 20241:06 pmRNSHolding(s) in Company
31st Dec 20248:39 amRNSUpdate on proposed sub-license of VAL201
30th Dec 20241:30 pmRNSResult of GM, Issue of Equity, Warrants and TVR
20th Dec 20247:00 amRNS-RValiRx launches new interactive investor website
10th Dec 20244:45 pmRNSBroker Offer Results & Director/PDMR Subscription
10th Dec 20243:03 pmRNSPosting of Circular and Notice of General Meeting
9th Dec 20247:00 amRNSConditional Fundraising & Launch of Broker Offer
22nd Nov 20247:00 amRNSInaphaea award of HEIF Funding and PhD sponsorship
20th Nov 20247:00 amRNSUpdate on proposed sub-license of VAL401
19th Nov 20247:00 amRNSContract Award
18th Nov 20247:00 amRNSFirst Sale of New Product Line
30th Oct 20247:00 amRNSUpdate on proposed sub-license of VAL201
18th Oct 20247:00 amRNSDirectorate Change
14th Oct 20247:00 amRNSInvestor Webinar
7th Oct 20247:00 amRNSInaphaea Co-Marketing Agreement
27th Sep 20247:00 amRNSHalf-year Report
26th Sep 20247:00 amRNSConclusion of Evaluation Project
24th Sep 20247:00 amRNSInaphaea Co-Marketing Agreement
18th Sep 20247:00 amRNSInaphaea Evaluation and Commercial Use Agreement
16th Sep 20247:00 amRNSInaphaea Co-Marketing Agreement
9th Sep 20247:00 amRNSInaphaea Evaluation and Commercial Use Agreement
9th Sep 20247:00 amRNSInvestor Evening
27th Aug 20247:00 amRNSInaphaea Evaluation and Commercial Use Agreement
12th Aug 20247:00 amRNSDirectorate Change
25th Jul 20247:00 amRNSDirectorate Changes
3rd Jul 20248:51 amRNSProposed Director Appointment
20th Jun 20245:56 pmRNSResult of AGM
19th Jun 202411:33 amRNSDirectorate Change
17th Jun 20247:00 amRNSInaphaea Contract Award
28th May 20247:00 amRNSInvestor Webinar
20th May 202412:00 pmRNSBusiness Update
16th May 20247:00 amRNSFurther re Final Results
15th May 20247:00 amRNSFinal Results and Notice of AGM
22nd Apr 20247:00 amRNSDirectorate Changes
21st Mar 20247:00 amRNSEvaluation Agreement with Imperial College London
19th Mar 20247:00 amRNSBoard Re-structuring and update on requisition
4th Mar 20245:47 pmRNSShareholder Requisition Notice
4th Mar 20247:00 amRNSProposed Appointment of Non-Executive Director
29th Feb 20242:00 pmRNSProposed Appointment of Non-Executive Director
13th Feb 20242:20 pmRNSFurther re Shareholder Requisition Notice
9th Feb 20245:06 pmRNSShareholder Requisition Notice

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.